IL260955A - A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure - Google Patents

A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure

Info

Publication number: IL260955A
Authority: IL; Israel
Prior art keywords: sacubitril; minitablet; valsartan; treatment; oral administration
Prior art date: 2016-02-03

Application number

IL260955A

Other languages

English (en)

Hebrew (he)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-03

Filing date

2018-08-02

Publication date

2018-09-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL260955(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-08-02 Application filed by Novartis Ag filed Critical Novartis Ag

2018-09-20 Publication of IL260955A publication Critical patent/IL260955A/en

Links

239000004072 C09CA03 - Valsartan Substances 0.000 title 1
206010019280 Heart failures Diseases 0.000 title 1
239000008185 minitablet Substances 0.000 title 1
PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 title 1
229960003953 sacubitril Drugs 0.000 title 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title 1
229960004699 valsartan Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL260955A 2016-02-03 2018-08-02 A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure IL260955A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP16154153		2016-02-03
US201662293005P	2016-02-09	2016-02-09
PCT/IB2017/050569 WO2017134597A1 (fr)	2016-02-03	2017-02-02	Formes pharmaceutiques à base de composés organiques

Publications (1)

Publication Number	Publication Date
IL260955A true IL260955A (en)	2018-09-20

Family

ID=55299378

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL260955A IL260955A (en)	2016-02-03	2018-08-02	A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure

Country Status (19)

Country	Link
US (3)	US20190054069A1 (fr)
EP (3)	EP3411018A1 (fr)
JP (4)	JP7156945B2 (fr)
KR (1)	KR102805176B1 (fr)
CN (1)	CN108601741B (fr)
AU (2)	AU2017215530B2 (fr)
CA (1)	CA3010778C (fr)
DK (1)	DK3411021T3 (fr)
ES (1)	ES3036922T3 (fr)
FI (1)	FI3411021T3 (fr)
HR (1)	HRP20250913T1 (fr)
HU (1)	HUE072182T2 (fr)
IL (1)	IL260955A (fr)
LT (1)	LT3411021T (fr)
PL (1)	PL3411021T3 (fr)
PT (1)	PT3411021T (fr)
RS (1)	RS67127B1 (fr)
SI (1)	SI3411021T1 (fr)
WO (2)	WO2017134597A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7156945B2 (ja)	2016-02-03	2022-10-19	ノバルティスアーゲー	有機化合物のガレヌス製剤
US20200276129A1 (en) *	2017-10-13	2020-09-03	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Tablet containing valsartan and sacubitril
WO2020039386A1 (fr) *	2018-08-23	2020-02-27	Novartis Ag	Nouvelle utilisation pharmaceutique pour le traitement d'une insuffisance cardiaque
WO2021172960A1 (fr) *	2020-02-26	2021-09-02	에리슨제약(주)	Préparation à libération prolongée pour traiter une insuffisance cardiaque, comprenant du sacubitril et du valsartan, préparation complexe à libération multiple comprenant celle-ci et procédé de préparation associé
KR102545274B1 (ko) *	2020-02-26	2023-06-20	에리슨제약(주)	사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
CA3203975A1 (fr)	2020-12-03	2022-06-09	Battelle Memorial Institute	Compositions de nanoparticules polymeres et de nanostructures d'adn et procedes d'administration non virale
KR20220091767A (ko) *	2020-12-24	2022-07-01	주식회사 보령	사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
JP2024505229A (ja) *	2021-01-31	2024-02-05	アレクシオンファーマシューティカルズ，インコーポレイテッド	銅代謝関連疾患又は障害を治療するための新規製剤
CA3216359A1 (fr)	2021-04-07	2022-10-13	Battelle Memorial Institute	Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
WO2023284724A1 (fr) *	2021-07-12	2023-01-19	上海博志研新药物技术有限公司	Composition à libération prolongée de sacubitril/valsartan sodique, son procédé de préparation et son utilisation
CN116687921A (zh) *	2023-06-14	2023-09-05	宁波大学	沙库巴曲缬沙坦类物质在制备神经毒性和认知障碍类药物的应用
AU2024353375A1 (en)	2023-09-29	2026-04-09	Battelle Memorial Institute	Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (fr)	2023-12-08	2025-06-12	Battelle Memorial Institute	Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE122007000050I1 (de)	1990-02-19	2007-11-08	Novartis Ag	Acylverbindungen
US5217996A (en)	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
AU2002316020B2 (en)	2001-07-16	2007-03-15	Astrazeneca Ab	Pharmaceutical formulation comprising a proton pump inhibitor and antacids
NZ533968A (en)	2002-01-17	2006-10-27	Novartis Ag	Pharmaceutical compositions comprising valsartan and nep inhibitors
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
AR057882A1 (es) *	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
NZ584686A (en) *	2007-11-06	2013-03-28	Novartis Ag	Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
US20110287100A1 (en)	2009-01-28	2011-11-24	Sabine Desset-Brethes	Galenic Formulations of Organic Compounds
AU2011293648B2 (en)	2010-08-24	2015-02-12	Novartis Ag	Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
AU2013304949C1 (en)	2012-08-24	2020-12-24	Novartis Ag	NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling
ES2968541T3 (es)	2013-08-26	2024-05-10	Novartis Ag	Tratamiento de enfermedades cardiovasculares
EP3038653A1 (fr)	2013-08-26	2016-07-06	Novartis AG	Nouvelle utilisation
JP7156945B2 (ja)	2016-02-03	2022-10-19	ノバルティスアーゲー	有機化合物のガレヌス製剤

2017
- 2017-02-02 JP JP2018540446A patent/JP7156945B2/ja active Active
- 2017-02-02 SI SI201731616T patent/SI3411021T1/sl unknown
- 2017-02-02 EP EP17703476.6A patent/EP3411018A1/fr active Pending
- 2017-02-02 PT PT177034774T patent/PT3411021T/pt unknown
- 2017-02-02 RS RS20250742A patent/RS67127B1/sr unknown
- 2017-02-02 HR HRP20250913TT patent/HRP20250913T1/hr unknown
- 2017-02-02 KR KR1020187022178A patent/KR102805176B1/ko active Active
- 2017-02-02 WO PCT/IB2017/050569 patent/WO2017134597A1/fr not_active Ceased
- 2017-02-02 AU AU2017215530A patent/AU2017215530B2/en active Active
- 2017-02-02 EP EP25175340.6A patent/EP4609912A3/fr active Pending
- 2017-02-02 WO PCT/IB2017/050573 patent/WO2017134600A1/fr not_active Ceased
- 2017-02-02 PL PL17703477.4T patent/PL3411021T3/pl unknown
- 2017-02-02 EP EP17703477.4A patent/EP3411021B1/fr active Active
- 2017-02-02 DK DK17703477.4T patent/DK3411021T3/da active
- 2017-02-02 FI FIEP17703477.4T patent/FI3411021T3/fi active
- 2017-02-02 JP JP2018540466A patent/JP6810152B2/ja active Active
- 2017-02-02 ES ES17703477T patent/ES3036922T3/es active Active
- 2017-02-02 LT LTEPPCT/IB2017/050573T patent/LT3411021T/lt unknown
- 2017-02-02 HU HUE17703477A patent/HUE072182T2/hu unknown
- 2017-02-02 CN CN201780009566.2A patent/CN108601741B/zh active Active
- 2017-02-02 CA CA3010778A patent/CA3010778C/fr active Active
- 2017-02-02 US US16/074,589 patent/US20190054069A1/en not_active Abandoned
2018
- 2018-08-02 IL IL260955A patent/IL260955A/en unknown
2019
- 2019-12-12 AU AU2019280026A patent/AU2019280026B2/en active Active
2022
- 2022-10-28 JP JP2022173240A patent/JP2023021991A/ja not_active Withdrawn
2023
- 2023-08-03 US US18/364,880 patent/US20240207227A1/en not_active Abandoned
2024
- 2024-08-23 JP JP2024141820A patent/JP2024160386A/ja active Pending
- 2024-12-05 US US18/970,329 patent/US20250325518A1/en active Pending

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEKSANDAR ALEKSOVSKI ET AL,, MINI-TABLETS: A CONTEMPORARY SYSTEM FOR ORAL DRUG DELIVERY IN TARGETED PATIENT GROUPS, 2 January 2015 (2015-01-02) *
ANONYMOUS,, EUROPEAN MEDICINES AGENCY DECISION P/0106/2014, 8 July 2016 (2016-07-08) *

Also Published As

Publication number	Publication date
US20190054069A1 (en)	2019-02-21
DK3411021T3 (da)	2025-08-18
LT3411021T (lt)	2025-08-25
AU2017215530A1 (en)	2018-07-26
JP7156945B2 (ja)	2022-10-19
JP6810152B2 (ja)	2021-01-06
KR102805176B1 (ko)	2025-05-12
EP3411018A1 (fr)	2018-12-12
EP4609912A2 (fr)	2025-09-03
RS67127B1 (sr)	2025-09-30
HUE072182T2 (hu)	2025-10-28
CN108601741A (zh)	2018-09-28
PL3411021T3 (pl)	2025-09-08
FI3411021T3 (fi)	2025-07-31
AU2019280026A1 (en)	2020-01-16
AU2019280026B2 (en)	2021-09-02
US20250325518A1 (en)	2025-10-23
CN108601741B (zh)	2022-05-24
CA3010778A1 (fr)	2017-08-10
WO2017134600A1 (fr)	2017-08-10
EP3411021A1 (fr)	2018-12-12
SI3411021T1 (sl)	2025-09-30
EP3411021B1 (fr)	2025-05-14
KR20180103940A (ko)	2018-09-19
JP2019504096A (ja)	2019-02-14
PT3411021T (pt)	2025-08-06
US20240207227A1 (en)	2024-06-27
ES3036922T3 (en)	2025-09-25
HRP20250913T1 (hr)	2025-09-26
AU2017215530B2 (en)	2019-09-12
JP2024160386A (ja)	2024-11-13
EP4609912A3 (fr)	2025-11-12
JP2019504094A (ja)	2019-02-14
CA3010778C (fr)	2024-02-27
WO2017134597A1 (fr)	2017-08-10
JP2023021991A (ja)	2023-02-14

Publication	Publication Date	Title
IL260955A (en)	2018-09-20	A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure
IL277648A (en)	2020-11-30	Medical microbiota for the treatment and/or prevention of food allergy
PL3577135T3 (pl)	2023-12-04	Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
ZA201908165B (en)	2023-07-26	Compounds for the prevention and treatment of diseases and the use thereof
IL264301A (en)	2019-02-28	Treatment of Fabry disease in ert-naive and ert-experienced patients
EP3104776A4 (fr)	2017-09-06	Diagnostic et traitement de troubles respiratoires
IL266047A (en)	2019-06-30	Methods and preparations for the treatment of Fabry disease
ZA201703346B (en)	2020-10-28	Conjugated bisphosphonates for the diagnosis and therapy of bone diseases
PT3277295T (pt)	2021-07-22	Composição para o tratamento de um estado metabólico patogénico da flora intestinal e de doenças derivadas
EP3268007A4 (fr)	2018-11-07	Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
EP3481323A4 (fr)	2020-02-26	Dispositifs de traitement de l'arythmie cardiaque et leur administration
EP3253451A4 (fr)	2018-02-21	Diagnostic et traitement de la douleur chronique
IL272097A (en)	2020-03-31	Compounds for the prevention and treatment of medical disorders and their uses
SG10201402819WA (en)	2016-01-28	Composition for prevention and treatment of joint pain and the method of preparation thereof
EP3250589A4 (fr)	2018-06-20	Agents diagnostiques et thérapeutiques
ZA201902090B (en)	2020-10-28	Combination treatments comprising administration of imidazopyrazinones
IL273470A (en)	2020-05-31	Semaglutide in medical treatment
EP3169321A4 (fr)	2018-03-07	Propolis et extraits de propolis pour traiter les cancers de la peau et améliorer la santé de la peau
IL274177A (en)	2020-06-30	Medical substances, their preparation and diagnostic method
PT3120852T (pt)	2019-07-16	Agente preventivo e/ou terapêutico para doenças imunitárias
IL252080A0 (en)	2017-07-31	Oral administration of drugs that are unstable or poorly absorbed
HUE065418T2 (hu)	2024-05-28	Indolin származékok fibrózisos betegségek kezelésére és/vagy megelõzésére
PL3710043T3 (pl)	2024-09-23	Fgf10 do leczenia chorób serca
IL257689B (en)	2021-03-25	Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
PL3509486T3 (pl)	2020-11-30	Urządzenie medyczne do wprowadzania cewników do ciała ludzkiego